
Arcutis Biotherapeutics fell 14.3% from $30.76 to $26.36, behind the S&P 500's +3.2%. Its worst day was Nov 5 (−20.7%), and its low came May 19 at $19.50.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.13 beat the $0.07 estimate on $129.5M revenue (est. $114.1M).
+5.8% · S&P 500 −0.6%
Arcutis Biotherapeutics shares rose 10.5%, while the S&P 500 rose 2.9%.
Story events cover the past 12 months · Times ET
+10.5% · S&P 500 +2.9%
EPS of $-0.09 missed the $-0.05 estimate on $105.4M revenue (est. $102.8M).
−14.5% · S&P 500 −0.3%
Arcutis Biotherapeutics closed at its lowest level of the year, 36.6% below where the year started.
−2.6% · S&P 500 −0.7%
EPS of $0.11 beat the $0.05 estimate on $129.9M revenue (est. $117.7M).
−2.5% · S&P 500 −0.2%
Arcutis Biotherapeutics shares rose 11.2%, while the S&P 500 fell 0.4%.
+11.2%, the year's best day · S&P 500 −0.4%
Arcutis Biotherapeutics shares rose 10.7%, while the S&P 500 rose 0.4%.
+10.7% · S&P 500 +0.4%
EPS of $0.06 missed the $0.17 estimate on $143.9M revenue (est. $142.4M).
−20.7%, the year's worst day · S&P 500 −4.4%
Where it ended: a close of $26.36 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $0.20, revenue est. $163.2M).
Nothing in the past 12 months.
All ARQT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ARQT and SPY from Benzinga historical bars. Not investment advice.